CCHT(SZ:000661)2022-12-07 08:38Group 1: Clinical Progress and Product Development - The long-acting growth hormone clinical trial is progressing smoothly, with completion expected in 2017 [1] - The new product, follicle-stimulating hormone, is being positioned in the market and is anticipated to perform well due to its mature product status and advanced recombinant technology [2] - The sales of growth hormone powder and water injections are expected to continue growing [2] Group 2: Financial Performance and Market Strategy - Huakang Pharmaceutical experienced negative revenue growth in the first three quarters due to multiple factors including public hospital bidding price reductions and rising production costs [3] - Huakang Pharmaceutical is refining its sales strategy to expand market coverage, aiming for a certain degree of growth in performance next year as market adjustments take place [3]